• About
  • Overview
  • Management
    • Dr. Joe Lewis
    • Dr. Bernd Janssen
    • Dr Fiona McLaughlin
    • Sally-Anne Watson
  • Supervisory Board
  • Scientific Advisory Board
  • Investors
• Programs
  • Mechanism of Action
  • Technology
  • Products
  • Technology Fact Sheet
• News
  • Latest News
  • Upcoming Events
  • Download Area
• Careers
  • Vacancies
• Contact
  • Contact
• Home
  • Home

Supervisory Board

Dr. David Owen O.B.E After graduating with a Ph.D. in pharmacology, Dr. Owen held various R&D positions in the pharmaceutical industry for 20 years (Sandoz and SmithKline). Before joining the MRC, in 1990, to led technology transfer activities, he led technology driven licensing agreements for SK&F, as Group Director, Compound & Technology Acquisitions. At the MRC, Dr. Owen led initiatives to develop technology transfer such that the MRC achieved an excellent reputation for its activities in patenting, licensing technologies, creating new "start-up" companies and generation of revenues. He was a founder and first Chairman of MVM Ltd., the MRC linked investment Fund that has raised more than £140 million to invest in early stage companies. In June 2001 he was appointed OBE for "services to medical research and technology transfer".

Dr. Sue Foden holds a number of non executive directorships with both public and private companies and public funding bodies in the biotech and healthcare field. Prior to this Dr. Foden held positions in VC, technology transfer and UK biotech. From 2000 to 2003, she was an Investor Director with the London- based VC firm Merlin Biosciences Ltd. From 1987 to 2000 she was CEO of the Technology transfer company, CRCT, and from 1998 to 2000 also of Cancer Research Ventures [CRV]. From 1983 to 1987 Dr. Foden headed up the academic liaison function at what was then Celltech Ltd, dealing with some of the earliest tech transfer deals in the UK and the precedents that these set. Dr Foden studied biochemistry at the University of Oxford where she obtained her MA and DPhil degrees.

Dr. Gerhard Keilhauer has broad experience in big pharma as well as in the biotech industry. Most recently he was Chief Development Officer of 4SC AG and for almost 7 years responsible for the company's preclinical and clinical development. Before this, he spent almost 16 years with BASF Pharma/Knoll AG in leading positions in R&D both in Europe as well as in the US. He is a biologist and chemist and holds a PhD in neurobiology from the University of Heidelberg.